(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 30.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Tg Therapeutics's revenue in 2025 is $531,898,000.On average, 10 Wall Street analysts forecast TGTX's revenue for 2025 to be $98,133,979,447, with the lowest TGTX revenue forecast at $93,447,400,453, and the highest TGTX revenue forecast at $102,185,520,636. On average, 10 Wall Street analysts forecast TGTX's revenue for 2026 to be $145,977,727,600, with the lowest TGTX revenue forecast at $131,779,869,897, and the highest TGTX revenue forecast at $159,394,488,804.
In 2027, TGTX is forecast to generate $184,637,241,513 in revenue, with the lowest revenue forecast at $150,184,853,051 and the highest revenue forecast at $213,213,942,693.